In Silico and Experimental Evidence for Theasaponin E2 as a Modulator of the AKT1/GSK-3β Signaling Axis in Osteoclast Differentiation
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27209255 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Lifang Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Osteoimmunology & Drug Discovery Research Group, Department of Biology, College of Science, Mathematics and Technology, Wenzhou-Kean University, 88 D…. Hauptthemen laut MEDLINE: Osteoclasts, Proto-Oncogene Proteins c-akt, Glycogen Synthase Kinase 3 beta, Cell Differentiation. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wenzhou-Kean University, International Frontier Interdisciplinary Research Institute of Wenzhou-Kean University, WKU-ISRG.
Abstract (Originalsprache)
Theasaponin E2 (TE2) is a triterpenoid saponin isolated from Camellia sinensis seeds with reported anti-inflammatory, antibacterial, and antitumor activities; however, its effects on osteoclasts remain unclear. In this study, TE2 markedly inhibited RANKL-induced osteoclast differentiation in RAW264.7 cells without affecting precursor-cell viability. TE2 also significantly reduced the number and viability of mature, differentiated osteoclasts. Mechanistically, TE2 suppressed RANKL-induced phosphorylation of AKT at Ser473 and GSK-3β at Ser9, as determined by ELISA. Molecular docking predicted that TE2 could interact with the interdomain allosteric pocket of AKT1 at the pleckstrin homology–kinase domain interface (PDB ID: 7NH5; docking score, −9.8 kcal/mol) and the ATP-binding pocket of GSK-3β (PDB ID: 5K5N; docking score, −7.7 kcal/mol). The selected docking poses contained multiple hydrogen-bonding interactions with donor–acceptor distances of 2.79–3.19 Å. Collectively, these findings indicate that TE2 suppresses osteoclast differentiation and reduces mature osteoclast viability, potentially through modulation of the AKT/GSK-3β signaling axis. TE2 may therefore represent a promising natural-product candidate for further investigation in conditions characterized by excessive osteoclast-mediated bone resorption.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Osteoimmunology & Drug Discovery Research Group, Department of Biology, College of Science, Mathematics and Technology, Wenzhou-Kean University, 88 Daxue Road, Wenzhou 325060, China.
- Dorothy and George Hennings College of Science, Mathematics and Technology, Kean University, 1000 Morris Ave, Union, NJ 07083, USA.
- Department of Chemistry, College of Science, Mathematics and Technology, Wenzhou-Kean University, 88 Daxue Road, Wenzhou 325060, China.
- International Frontier Interdisciplinary Research Institute (IFIRI) of Wenzhou-Kean University, Wenzhou 325060, China.
ORCID-Profile: Lifang Zhang, Vishwa Deepak
Förderung
- Wenzhou-Kean University
- International Frontier Interdisciplinary Research Institute of Wenzhou-Kean University
- WKU-ISRG
Zitieren
APA
Zhang, L., Ding, Y., Bao, X., & Deepak, V. (2026). In Silico and Experimental Evidence for Theasaponin E2 as a Modulator of the AKT1/GSK-3β Signaling Axis in Osteoclast Differentiation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27209255
Vancouver
Zhang L, Ding Y, Bao X, Deepak V. In Silico and Experimental Evidence for Theasaponin E2 as a Modulator of the AKT1/GSK-3β Signaling Axis in Osteoclast Differentiation. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27209255
BibTeX
@article{Zhang2026,
author = {Zhang, Lifang and Ding, Yili and Bao, Xinyi and Deepak, Vishwa},
title = {In Silico and Experimental Evidence for Theasaponin E2 as a Modulator of the AKT1/GSK-3β Signaling Axis in Osteoclast Differentiation},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27209255}
}
EUVIMED